Sugi Predict

Sugi Predict / Compounds / SCHEMBL1774203

SCHEMBL1774203

SCHEMBL1774203

CC(C)(C)OC(=O)C(C)(C)NCc1ccccc1Cc1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA7 P43166 1/20 0.43
▸ CA14 Q9ULX7 1/20 0.43
▸ ITGA4 P13612 1/20 0.42
▸ ITGB7 P26010 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ PPARA Q07869 2/20 0.40
▸ PPARG P37231 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ KMT2A Q03164 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ AKT1 P31749 2/20 0.39
▸ HDAC3 O15379 1/20 0.38
▸ HDAC1 Q13547 1/20 0.38
▸ HDAC2 Q92769 1/20 0.38
▸ NCOR2 Q9Y618 1/20 0.38
▸ MAPT P10636 1/20 0.37
▸ HRH1 P35367 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL320060 0.85 CA12 (0.52) CA12CA1CA7CA14ITGA4
SCHEMBL1192098 0.78 RIPK1 (0.49) ITGA4ITGB7L3MBTL1HRH1PTGDR2
SCHEMBL4704671 0.75 IDO1 (0.50) CA12CA1CA7CA14PPARA
SCHEMBL21328307 0.72 RIPK1 (0.47) CA12CA1CA7CA14L3MBTL1
SCHEMBL8026319 0.72 GAA (0.51) L3MBTL1ATMKMT2AMAPT
SCHEMBL1773384 0.69 PTGER3 (0.39) CA12CA1CA7CA14ITGA4
SCHEMBL1773383 0.69 PTGER3 (0.39) CA12CA1CA7CA14ITGA4
SCHEMBL17541033 0.69 MMP8 (0.56) KMT2AMAPTHSP90AA1
SCHEMBL1151094 0.69 MEN1 (0.56) CA12CA1CA7CA14PPARA
SCHEMBL8577476 0.68 ALDH1A1 (0.54) L3MBTL1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-05-12 — — US disclosed
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-05-12 — — US disclosed
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof SANOFI-AVENTIS (FR) 2011-05-12 — — US disclosed
EP-2242747-A1 SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF Sanofi-Aventis (FR) 2010-10-27 — — EP disclosed
WO-2009097997-A1 SUBSTITUTED IMIDAZOLIDINE-2,4-DIONES, METHOD FOR THE PRODUCTION THEREOF, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF SANOFI-AVENTIS (FR) 2009-08-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112097-A1 Substituted imidazoline-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof GIPR, PGC, DDC CA12 4453/4885CA1 4524/4885CA7 1923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.